A Study of LY3857210 in Healthy Participants

Lilly

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: LY3857210

Study type

Interventional

Funder types

Industry

Identifiers

NCT05292040

J3O-MC-LSBA (Other Identifier)

18313

Details and patient eligibility

About

The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand [18F]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.

Enrollment

10 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Overtly healthy male or female participants as determined by medical evaluation
Have body weight ≥ 45 kilograms (kg) and body mass index (BMI) within the range 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive)
Are males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential

Exclusion criteria

Have contraindications to undergoing magnetic resonance imaging (MRI) examination including but not limited to implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips, and other medical implants that have not been certified for head MRI
Have clinically significant findings on the screening MRI scan, as judged by the investigator
Suffer from claustrophobia and would be unable to tolerate the confined spaces of MRI or PET camera